Viatris Appoints New E Channel Assistant

Viatris has hired a new e channel assistant, Subhashini. She will be responsible for the company's biosimilars portfolio. The company will be known as Viatris after it merges with Upjohn (a division of Pfizer). Subhashini says she is thankful for the opportunity to broaden her skill set and hopes to inspire others to pursue careers in science.

Subhashini is a Viatris e channel assistant

Subhashini Krishnamurthy is a member of the Viatris legal team and is a patent diligence specialist for new biosimilars. In this role, she aims to understand the technicalities and risks associated with a product and develop an intellectual property strategy and provide feedback as needed. She oversees a team located across the U.S., Europe, and India, and has extensive experience in managing intellectual property in different regions. In addition to her role in the legal department, Subhashini is also responsible for advising the company's litigation team on its business strategies.

Subhashini studied science at Osmania University in India, earning a master's degree in microbiology. She then moved to the U.S. to pursue her doctorate in immunology. She was nearly certain that she would end up working in the field of science, but her passion for patent law led her to a completely different career path.
Bill Szablewski joins Viatris as Head of Capital Markets

Bill Szablewski is a seasoned finance executive with nearly two decades of experience in the healthcare industry. Prior to joining Viatris, he served as Global Finance Director for CNS and Pain Care at Teva Pharmaceuticals. In this role, he was responsible for corporate finance, M&A, and equity and debt financing. He also led risk management, investor relations, and global pipeline initiatives.

Viatris has named Bill Szablewski as its new head of capital markets. Szablewski will oversee the company's treasury and investor relations, and will also be responsible for fostering the company's brand and reputation. He will report to Sanjeev Narula, the current CFO at Upjoin.

Viatris also uses non-GAAP financial measures, including adjusted gross profit and gross margins, free cash flow and adjusted net earnings per share. These measures are used internally by the company's management to measure performance, plan for future investments, and determine incentive-based awards.
Viatris settles lawsuit for EpiPen

Viatris, the company that makes the EpiPen allergy treatment, has agreed to settle a lawsuit over the monopoly it has over the product. The lawsuit claims that the company engaged in a scheme to delay the entry of generic EpiPens. The settlement does not include any admission of liability and remains subject to court approval. リパクレオン

Viatris, formerly known as Mylan Pharmaceuticals, agreed to pay $264 million to settle a class action lawsuit alleging that it abused its monopoly over EpiPen auto-injectors to increase their prices. Viatris indicated in its quarterly report that the settlement did not admit to wrongdoing. The original damages sought by the plaintiffs were $1 billion. The company allegedly agreed to delay the release of a generic EpiPen, allowing Mylan to raise the price of EpiPen without any competition.

EpiPen is a life-saving auto-injector that can be used to treat an allergic reaction quickly and effectively. It is sold by Mylan and Pfizer, and the package was only $100 when Mylan acquired the rights in 2007. It now costs about $650 without discounts.